非侵入性产前检测市场规模、份额、成长分析（按产品、检测方法、技术、妊娠风险、妊娠週龄、应用和地区划分）- 产业预测，2025 年至 2032 年

2023 年全球无创产前检测 (NIPT) 市场规模价值 38 亿美元，预计将从 2024 年的 41.6 亿美元增长到 2032 年的 86.7 亿美元，预计到 2032 年将达到 12 亿美元。复合年增长率为9.6%。

非侵入性肠外筛检市场主要集中在非侵入性产前检测(NIPT)，受技术进步和母亲年龄增长的推动，该市场已显示出显着的增长，这与更高的染色体异常风险相关。这种基因检测方法分析母体血清中的胎儿无细胞DNA，可以早期发现唐氏症和透纳氏症疾病。目前，世界各地广泛使用多种 NIPT，包括 MaterniT21 PLUS、Harmony 和 Panorama。随着 NIPT 报销额度的提高以及向非侵入性方法的转变，市场有望扩张。然而，合格人员短缺和严格的监管要求等挑战可能会阻碍进展。新兴市场，特别是亚太地区，为该领域的成长提供了新的机会。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

全球无创产前检测 (NIPT) 市场规模（按产品）

• 市场概况
• 耗材
• 试剂
• 装置

全球无创产前检测 (NIPT) 市场规模（按检测方法）

• 市场概况
• 超音波检测
• 生化筛检测试
• 母体血浆中的游离 DNA 检测

全球无创产前检测 (NIPT) 市场规模（按技术）

• 市场概况
• NGS
• 阵列技术
• PCR
• 其他的

全球无创产前检测 (NIPT) 市场规模（按怀孕风险）

• 市场概况
• 高风险
• 平均风险
• 低风险

全球无创产前检测 (NIPT) 市场规模（按孕龄）

• 市场概况
• 0 - 12 週
• 13-24 週
• 25-36 週

全球无创产前检测 (NIPT) 市场规模（按应用）

• 市场概况
• 三体性
• 微缺失症候群
• 其他的

全球无创产前检测 (NIPT) 市场规模（按最终用户）

• 市场概况
• 医院
• 诊所
• 诊断实验室
• 其他的

全球无创产前检测 (NIPT) 市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Berry Genomics Co. Ltd.（China）
• BGI Genomics Co., Ltd.（China）
• Eurofins LifeCodexx GmbH（Germany）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GE Healthcare（United States）
• Natera, Inc.（United States）
• Laboratory Corporation of America Holdings（LabCorp）（United States）
• Illumina, Inc.（United States）
• Myriad Genetics, Inc.（United States）
• Quest Diagnostics Incorporated（United States）
• Thermo Fisher Scientific Inc.（United States）
• Sonic Healthcare Limited（Australia）
• Centogene NV（Germany）
• PerkinElmer, Inc.（United States）
• Cordlife Group Limited（Singapore）

结论和建议

Global Non-Invasive Prenatal Testing (NIPT) Market size was valued at USD 3.8 billion in 2023 and is poised to grow from USD 4.16 billion in 2024 to USD 8.67 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The non-invasive parenteral screening market, predominantly focused on non-invasive prenatal testing (NIPT), is witnessing significant growth driven by advancements in technology and increasing maternal age, which correlates with higher risks for chromosomal abnormalities. This genetic testing method analyzes fetal cell-free DNA in maternal blood serum, enabling early detection of conditions such as Down syndrome and Turner syndrome. Various NIPTs, including MaterniT21 PLUS, Harmony, and Panorama, are now widely available globally. Facilitated by rising reimbursements for NIPT and a shift towards non-invasive methods, the market is poised for expansion. However, challenges such as a lack of qualified personnel and stringent regulatory requirements may impede progress. Emerging markets, especially in the Asia-Pacific region, present new opportunities for growth in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Invasive Prenatal Testing (Nipt) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Invasive Prenatal Testing (NIPT) Market Segmental Analysis

Global Non-Invasive Prenatal Testing (NIPT) Market is segmented by Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User and region. Based on Product, the market is segmented into Consumables, Reagents and Instruments. Based on Testing Method, the market is segmented into Ultrasound Detection, Biochemical Screening Tests and Cell-Free DNA in Maternal Plasma Tests. Based on Technology, the market is segmented into NGS, Array Technology, PCR and Others. Based on Pregnancy Risk, the market is segmented into High Risk, Average Risk and Low Risk. Based on Gestation Period, the market is segmented into 0-12 Weeks, 13-24 Weeks and 25-36 Weeks. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome and Others. Based on End User, the market is segmented into Hospitals, Clinics, Diagnostic Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Invasive Prenatal Testing (NIPT) Market

The Global Non-Invasive Prenatal Testing (NIPT) market is driven by the increasing demand for precise and advanced screening techniques that enable early detection of genetic disorders in infants. Companies are focusing on developing innovative noninvasive diagnostic solutions and forming strategic partnerships to enhance their presence in the market. Recent progress in human genome sequencing has significantly improved the identification of aneuploidies in newborns. Notably, Progenity, Inc. launched the Resura Prenatal Diagnostic for Monogenic Disease in 2019, marking a milestone as the first flexible, noninvasive test for single-gene conditions. Furthermore, many countries are adopting non-invasive prenatal screening protocols to effectively detect chromosomal abnormalities.

Restraints in the Global Non-Invasive Prenatal Testing (NIPT) Market

The growth of the Global Non-Invasive Prenatal Testing (NIPT) market faces several significant restraints, primarily stemming from economic and educational barriers. High testing costs, particularly in developing nations where prices range from USD 350 to USD 400, render these tests unaffordable for many, thus hindering widespread adoption. Additionally, a general lack of awareness regarding genetic disorders among the population in emerging markets further complicates acceptance. Coupled with decreasing per capita healthcare expenditure and insufficient reimbursement policies for these tests, these factors collectively contribute to a constrained growth environment for the NIPT market on a global scale.

Market Trends of the Global Non-Invasive Prenatal Testing (NIPT) Market

The Global Non-Invasive Prenatal Testing (NIPT) market is witnessing significant growth as healthcare trends increasingly favor non-invasive methodologies over traditional invasive procedures. Advances in technology and clinical validation have positioned NIPT as the preferred choice for prenatal screening, driven by its therapeutic benefits and cost-effectiveness. Regulatory frameworks in various countries, such as the Netherlands, have further reinforced the adoption of non-invasive diagnostics, establishing them as standard practice. This surge in utilization highlights a shift toward safer prenatal options, with NIPT rapidly gaining traction worldwide, despite the ongoing relevance of invasive tests for specific medical conditions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Product & CAGR (2025-2032)

• Market Overview
• Consumables
• Reagents
• Instruments

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Testing Method & CAGR (2025-2032)

• Market Overview
• Ultrasound Detection
• Biochemical Screening Tests
• Cell-Free DNA in Maternal Plasma Tests

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Technology & CAGR (2025-2032)

• Market Overview
• NGS
• Array Technology
• PCR
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Pregnancy Risk & CAGR (2025-2032)

• Market Overview
• High Risk
• Average Risk
• Low Risk

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Gestation Period & CAGR (2025-2032)

• Market Overview
• 0-12 Weeks
• 13-24 Weeks
• 25-36 Weeks

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Application & CAGR (2025-2032)

• Market Overview
• Trisomy
• Microdeletion Syndrome
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Laboratories
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size & CAGR (2025-2032)

• North America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • US
  • Canada
• Europe (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Berry Genomics Co. Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins LifeCodexx GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (LabCorp) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonic Healthcare Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centogene N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cordlife Group Limited (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations